Nyxthracis (previously Obiltoxaximab SFL) האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuni serumi i homologna, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Serynox 50%/50% V/V medicinski plin, stlačen קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

serynox 50%/50% v/v medicinski plin, stlačen

messer croatia plin d.o.o., industrijska 1, zaprešić, hrvatska - dušikov (i) oksid kisik - medicinski plin, stlačeni - 50%/50% v/v - urbroj: svaki spremnik sadrži 50% v/v dušičnog oksidula i 50% v/v kisika pod tlakom od 170 bara (15°c)

VESSEL 600LSU/2ml Rastvor za injekciju מונטנגרו - קרואטית - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

vessel 600lsu/2ml rastvor za injekciju

"goodwill pharma" druŠtvo sa ograniČenom odgovornoŠĆu podgorica - sulodeksid - rastvor za injekciju - 600lsu/2ml

VESSEL 250LSU Kapsula, meka מונטנגרו - קרואטית - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

vessel 250lsu kapsula, meka

"goodwill pharma" druŠtvo sa ograniČenom odgovornoŠĆu podgorica - sulodeksid - kapsula, meka - 250lsu

Blincyto האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

HyQvia האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

hyqvia

baxalta innovations gmbh - imunoglobulina osoba normalan - sindromi imunološke manjkavosti - imuni serumi i homologna, - hormonske terapije kod odraslih, djece i adolescenata (0-18 godina): sindromi primarne imunodeficijencije povrede антителообразования. hypogammaglobulinaemia i rekurentne bakterijske infekcije u bolesnika s kroničnim лимфолейкозом (ХЛЛ), u kojima su preventivni antibiotici su beskorisni ili contra. hypogammaglobulinaemia i rekurentne bakterijske infekcije pri višestrukom myelomi (mm) pacijenata. hypogammaglobulinaemia u bolesnika prije i nakon аллогенной transplantacije гемопоэтических matičnih stanica (ТГСК).

Kuvan האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

kuvan

biomarin international limited - Сапроптерин дигидрохлорид - phenylketonurias - drugi gastrointestinalni trakt i metabolizam, lijekovi, - slika je indicirana za liječenje hiperfenilalaninemije (hpa) u odraslih i pedijatrijskih bolesnika svih dobnih skupina s fenilketonurijom (pku) za koje je pokazano da reagiraju na takav tretman. Кувинский je također indiciran za liječenje hyperphenylalaninaemia (hpa) u odraslih i pedijatrijski pacijenti svih uzrasta s tetrahydrobiopterin (СҺ4) nedostatak, koji su pokazali da će odgovoriti na takav tretman.